A study of Centchroman users with special reference to its contraceptive benefit

Goter Doke, Jyoti Kamda


Background: Centchroman (INN: Ormeloxifene), was developed at CDRI, Lucknow in 1967. This drug was finally approved and licensed in 1991 and launched as Saheli and Choice-7 for marketing in 1992. The Ministry of Health and Family Welfare, India has now introduced centchroman in national family planning programme under the trade name “Chhaya” from April 2016. Centchroman is a novel nonsteroidal contraceptive that inhibits the fertilised ovum from implantation and thus prevents pregnancy. The aim of this study was to assess the effectiveness, side effects, discontinuation rates and failure rate among the users of Centchroman (Chhaya).

Methods: The retrospective study was conducted by reviewing the records of Centchroman (Chhaya) contraceptives acceptor over the period of one year from September 2017 to August 2018 in family welfare clinic of Department of Obstetrics and Gynecology at Tomo Riba Institute of Health and Medical Science, a tertiary level center in Naharlagun, Arunachal Pradesh, India.

Results: A total of 146 women were evaluated for the study. Majority of the women were in the age group of 20-30 years (76.02%) with mean age of 26 years. Most of the centchroman acceptors were multipara (74.65%) and women in post-abortion (38.35%) and postpartum group (36.3%). Duration of use ranged from 3 months in 146 women to 12 months in 98 women. The discontinuation rate was 31.5%. The major menstrual complaint was delayed menstrual cycle in 15.06% women and irregular cycle in 10.95%. Of the 146 women in the study group, pregnancy occurred in 3 women. Pearl index calculated for centchroman was 2.05/HWY.

Conclusions: Centchroman is a non-steroidal, non-hormonal oral contraceptive drug with good therapeutic efficacy and a favourable side effect profile. Centchroman has an important place in postpartum contraception due to its safety profile in breastfeeding women.


Centchroman, Chhaya, Contraceptive, Failure rate, Ormeloxifene

Full Text:



Kamboj VP, Ray S, Anand N. Centchroman: A safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front Biosci (Elite Ed). 2018;10:1-14.

Lerner LJ, Holthaus JF, Thompson CR. A nonsteroidal estrogen antagonist 1-(p-2-diethylaminiethexyphenyl)-2-phenyl methoxyphenylethanol. Endocrinol. 1958;63(3):295-318.

Kumar N, Pant G, Kulkarni SR. The journey of the world’s first non-steroidal contraceptive from Academic venture to National family programme. Available at: Accessed on 15th September 2019.

Oral Contraceptive Pills - National Health Mission. Available at: Accessed om 15th September 2019.

Kamboj VP, Kar AB, Ray S, Grover PK, Anand N. Antifertility activity of 3,4-trans-2,2-dimethyl-3-phenyl-4-p(β-pyrolidinethoxy)-phenyl-7-methoxychroman. Indian J Exp Biol. 1971;9:103-4.

Kamboj VP, Setty BS, Chandra H, Roy SK, Kar AB. Biological profile of Centchroman: a new post- coital contraceptive. Indian J Exp Biol. 1977;15:1144-50.

Lal J, Asthana OP, Nityanand S, Gupta RC. Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contracept. 1995;52(5):297-300.

Kamboj VP, Ray S, Dhawan BN. Centchroman. Drugs Today. 1992;28:227-32.

Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21(4):302-47.

Nityanand S, Kamboj VP, Chandrawati, Das K, Gupta K, Rohtagi P, et al. Contraceptive efficacy and safety of Centchroman with biweekly-cum-weekly schedule. In: Current concepts in fertility regulation and reproduction, Eds: CP Puri, PFA VanLook New Delhi, Wiley Eastern Ltd; 1994:61-68.

Cleland J, Bernstein S, Ezeh A, Faundes A, Glasier A, Innis J. Family planning: the unfinished agenda. Lancet. 2006;368(9549):1810-27.

Nair HS, Jayasimhan P. A prospective study of centchroman users with special reference to its contraceptive benefit. J. Evid Based Med Healthc. 2016;3(98):5374-80.